Impact of insurance coverage on HIV transmission potential among antiretroviral therapy-treated youth living with HIV.

TitleImpact of insurance coverage on HIV transmission potential among antiretroviral therapy-treated youth living with HIV.
Publication TypeJournal Article
Year of Publication2018
AuthorsWood S, Ratcliffe S, Gowda C, Lee S, Dowshen NL, Gross R
JournalAIDS
Volume32
Start Page895
Issue7
Pagination895-902
Date Published2018 Apr 24
ISSN1473-5571
Abstract

OBJECTIVE: To identify the prevalence of high HIV transmission potential in a cohort of youth living with HIV (YLWH), and determine the impact of insurance coverage on potential for HIV transmission.

DESIGN: Retrospective cohort study of antiretroviral therapy (ART)-treated YLWH at a US adolescent HIV clinic, 2002-2015.

METHODS: The primary exposure was presence or absence of insurance, defined as private, public or pharmacy-only coverage. The primary outcome was high HIV transmission potential, defined as time-concurrent incident bacterial STI (gonorrhea, chlamydia or syphilis) and HIV RNA greater than 1500 copies/ml. Marginal structural models adjusting for baseline demographic covariates, prior history of STI and time-varying retention in care assessed the relationship between insurance status and HIV transmission potential.

RESULTS: Participants (n = 240) were followed for a median of 22 (IQR 8.1-49) months after ART initiation, and were predominately African-American men and transgender women who have sex with men, with a median age at HIV diagnosis of 19 years (IQR 17-21). We identified 37 (15%) participants with at least one episode of high HIV transmission potential. Insurance coverage was associated with a greater than 50% lower odds of high HIV transmission potential (aOR 0.46, 95% CI 0.26-0.84), and history of STI at or before entry to HIV care conferred more than three-fold higher odds of high transmission potential (aOR 3.21, 95% CI 1.55-6.63).

CONCLUSION: We found 17% of YLWH to have episodic high HIV transmission potential despite receiving ART. Insurance coverage, including pharmacy-only benefits, was protective against transmission risk, suggesting a pivotal role for universal ART coverage in treatment as prevention.

DOI10.1097/QAD.0000000000001772
Alternate JournalAIDS
PubMed ID29424777